Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring

Outcomes in RAS-mutant metastatic colorectal cancer (mCRC) remain poor and patients have limited therapeutic options. Adavosertib is the first small-molecule inhibitor of WEE1 kinase. We hypothesized that aberrations in DNA replication seen in mCRC with both RAS and TP53 mutations would sensitize tu...

Descripción completa

Detalles Bibliográficos
Autores principales: Seligmann, Jenny F., Fisher, David J., Brown, Louise C., Adams, Richard A., Graham, Janet, Quirke, Philip, Richman, Susan D., Butler, Rachel, Domingo, Enric, Blake, Andrew, Yates, Emma, Braun, Michael, Collinson, Fiona, Jones, Rob, Brown, Ewan, de Winton, Emma, Humphrey, Timothy C., Parmar, Mahesh, Kaplan, Richard, Wilson, Richard H., Seymour, Matthew, Maughan, Timothy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601321/
https://www.ncbi.nlm.nih.gov/pubmed/34538072
http://dx.doi.org/10.1200/JCO.21.01435

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8601321/
https://www.ncbi.nlm.nih.gov/pubmed/34538072
http://dx.doi.org/10.1200/JCO.21.01435

Ejemplares similares